---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114895"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T06:44:00.339155+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech receives Nasdaq bid price deficiency notice; 180-day cure period through May 1, 2023

## Summary
- Received Nasdaq letter on Oct 31, 2022 for bid price below $1.00 for 30 consecutive business days.
- Non-compliance with Nasdaq Listing Rule 5550(a)(2) for common stock (FBIO).
- 180-day grace period through May 1, 2023; must close at $1.00+ for 10 consecutive days to cure.
- If not cured, may be eligible for another 180 days if meets initial listing criteria and market value requirement.
- Company evaluating options to remedy bid price deficiency; no decision made yet.

## SEC filing metadata
- accession: 0001104659-22-114895
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465922114895/0001104659-22-114895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465922114895/tm2229531-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114895
- JSON: https://secwatch.observer/filing/0001104659-22-114895.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114895.txt

## Key facts
- Listing & Compliance Notices
  Fortress Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: October 31, 2022, Fortress Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s notice has no immediate effect on the listing of the C
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465922114895/0001104659-22-114895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.